Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-12-18 Proxy Solicitation & In…
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Oncoinvent ASA: Notice of Extraordinary General Meeting - Attachment: Oncoinvent_ASA_Notice_EGM_8_January_2026.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official 'Notice of Extraordinary General Meeting' (Innkalling til ekstraordinær generalforsamling) for Oncoinvent ASA. It outlines the agenda items, including proposals for share capital increases, reverse share splits, and capital reductions, which are typical subjects for shareholder voting at an EGM. As it provides the materials and agenda for shareholders to prepare for the meeting, it falls under the category of Proxy Solicitation & Information Statement.
2025-12-18 Norwegian
Oncoinvent ASA: Notice of Extraordinary General Meeting
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) notifying shareholders of an upcoming Extraordinary General Meeting (EGM). It explicitly states that the notice and attachments are provided via a link, which aligns with the 'Menu vs Meal' rule for a Report Publication Announcement (RPA). While it concerns a meeting, it is an announcement of the meeting materials rather than the proxy statement itself or the voting results.
2025-12-18 English
Oncoinvent ASA: New share capital registered
Share Issue/Capital Change Classification · 100% confidence The document announces the registration of new share capital with the Norwegian Register of Business Enterprises following a rights issue and the issuance of underwriting commission shares. This directly relates to changes in the company's capital structure and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-12-10 English
Flaggemelding – Hadean Ventures AS / HVentures AB / Hadean Growth Fund I AS1 – Oncoinvent AS (ONCIN)
Major Shareholding Notification Classification · 100% confidence The document is a 'Flaggemelding' (Flagging Notification) which is the Norwegian term for a major shareholding notification. It explicitly states that the entities have crossed a threshold of 10% ownership in Oncoinvent AS (ONCIN) following a share subscription. This fits the definition of a Major Shareholding Notification (MRQ).
2025-12-08 Norwegian
Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology
Regulatory Filings Classification · 90% confidence The document is a press release issued by Oncoinvent announcing the publication of clinical trial results in a peer-reviewed journal. It provides a summary of the study findings, mentions ongoing clinical trials, and includes contact information. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is a general corporate announcement regarding clinical progress, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for general corporate announcements.
2025-12-08 English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_12_05_PDMR_Attachment_subscription_and_allocation_of_UWC_shares.pdf
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them' (PDMR notifications). It explicitly lists the names of the individuals/entities, their relationship to the issuer (Oncoinvent ASA), the nature of the transaction (subscription of shares), and the transaction details (price, volume, date). This is a classic 'Director's Dealing' or 'Insider Trading' disclosure, which falls under the DIRS category.
2025-12-08 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.